Cargando…

p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome

Cell cycle progression is regulated by the combined action of cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors (CDKi), which are negative cell cycle regulators. p27(KIP1) is a CDKi key in cell cycle regulation, whose degradation is required for G1/S transition. In spite of the absence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sáez, Al, Sánchez, E, Sánchez-Beato, M, Cruz, M A, Chacón, I, Muñoz, E, Camacho, F I, Martínez-Montero, J C, Mollejo, M, Garcia, J F, Piris, M A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363083/
https://www.ncbi.nlm.nih.gov/pubmed/10424746
http://dx.doi.org/10.1038/sj.bjc.6690539
_version_ 1782153615732899840
author Sáez, Al
Sánchez, E
Sánchez-Beato, M
Cruz, M A
Chacón, I
Muñoz, E
Camacho, F I
Martínez-Montero, J C
Mollejo, M
Garcia, J F
Piris, M A
author_facet Sáez, Al
Sánchez, E
Sánchez-Beato, M
Cruz, M A
Chacón, I
Muñoz, E
Camacho, F I
Martínez-Montero, J C
Mollejo, M
Garcia, J F
Piris, M A
author_sort Sáez, Al
collection PubMed
description Cell cycle progression is regulated by the combined action of cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors (CDKi), which are negative cell cycle regulators. p27(KIP1) is a CDKi key in cell cycle regulation, whose degradation is required for G1/S transition. In spite of the absence of p27(KIP1) expression in proliferating lymphocytes, some aggressive B-cell lymphomas have been reported to show an anomalous p27(KIP1) staining. We analysed p27(KIP1) expression in a series of Diffuse Large B-cell Lymphoma (DLBCL), correlating it with the proliferative index and clinical outcome, to characterize the implications of this anomalous staining in lymphomagenesis in greater depth. For the above mentioned purposes, an immunohistochemical technique in paraffin-embedded tissues was employed, using commercially available antibodies, in a series of 133 patients with known clinical outcomes. Statistical analysis was performed in order to ascertain which clinical and molecular variables may influence outcome, in terms of disease-free survival (DFS) and overall survival (OS). The relationships between p27(KIP1) and MIB-1 (Ki-67) were also tested. An abnormally high expression of p27(KIP1) was found in lymphomas of this type. The overall correlation between p27(KIP1) and MIB-1 showed there to be no significant relationship between these two parameters, this differing from observations in reactive lymphoid and other tissues. Analysis of the clinical relevance of these findings showed that a high level of p27(KIP1) expression in this type of tumour is an adverse prognostic marker, in both univariate and multivariate analysis. These results show that there is abnormal p27(KIP1) expression in DLBCL, with adverse clinical significance, suggesting that this anomalous p27(KIP1) protein may be rendered non-functional through interaction with other cell cycle regulator proteins. © 1999 Cancer Research Campaign
format Text
id pubmed-2363083
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23630832009-09-10 p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome Sáez, Al Sánchez, E Sánchez-Beato, M Cruz, M A Chacón, I Muñoz, E Camacho, F I Martínez-Montero, J C Mollejo, M Garcia, J F Piris, M A Br J Cancer Regular Article Cell cycle progression is regulated by the combined action of cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors (CDKi), which are negative cell cycle regulators. p27(KIP1) is a CDKi key in cell cycle regulation, whose degradation is required for G1/S transition. In spite of the absence of p27(KIP1) expression in proliferating lymphocytes, some aggressive B-cell lymphomas have been reported to show an anomalous p27(KIP1) staining. We analysed p27(KIP1) expression in a series of Diffuse Large B-cell Lymphoma (DLBCL), correlating it with the proliferative index and clinical outcome, to characterize the implications of this anomalous staining in lymphomagenesis in greater depth. For the above mentioned purposes, an immunohistochemical technique in paraffin-embedded tissues was employed, using commercially available antibodies, in a series of 133 patients with known clinical outcomes. Statistical analysis was performed in order to ascertain which clinical and molecular variables may influence outcome, in terms of disease-free survival (DFS) and overall survival (OS). The relationships between p27(KIP1) and MIB-1 (Ki-67) were also tested. An abnormally high expression of p27(KIP1) was found in lymphomas of this type. The overall correlation between p27(KIP1) and MIB-1 showed there to be no significant relationship between these two parameters, this differing from observations in reactive lymphoid and other tissues. Analysis of the clinical relevance of these findings showed that a high level of p27(KIP1) expression in this type of tumour is an adverse prognostic marker, in both univariate and multivariate analysis. These results show that there is abnormal p27(KIP1) expression in DLBCL, with adverse clinical significance, suggesting that this anomalous p27(KIP1) protein may be rendered non-functional through interaction with other cell cycle regulator proteins. © 1999 Cancer Research Campaign Nature Publishing Group 1999-07 /pmc/articles/PMC2363083/ /pubmed/10424746 http://dx.doi.org/10.1038/sj.bjc.6690539 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Sáez, Al
Sánchez, E
Sánchez-Beato, M
Cruz, M A
Chacón, I
Muñoz, E
Camacho, F I
Martínez-Montero, J C
Mollejo, M
Garcia, J F
Piris, M A
p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome
title p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome
title_full p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome
title_fullStr p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome
title_full_unstemmed p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome
title_short p27(KIP1) is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome
title_sort p27(kip1) is abnormally expressed in diffuse large b-cell lymphomas and is associated with an adverse clinical outcome
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363083/
https://www.ncbi.nlm.nih.gov/pubmed/10424746
http://dx.doi.org/10.1038/sj.bjc.6690539
work_keys_str_mv AT saezal p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT sancheze p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT sanchezbeatom p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT cruzma p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT chaconi p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT munoze p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT camachofi p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT martinezmonterojc p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT mollejom p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT garciajf p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome
AT pirisma p27kip1isabnormallyexpressedindiffuselargebcelllymphomasandisassociatedwithanadverseclinicaloutcome